Abstract
Background
Treatment with antipsychotic drugs is widely associated with metabolic side-effects such as overweight and disturbed glucose metabolism, but the pathophysiological mechanisms are unclear.
Methods
Fifty-one non-diabetic, antipsychotic-treated male patients ((mean±standard deviation) age: 33.1 ±6.7 years; body mass index (BMI) 26.0 ±4.7 kg/m2; waist circumference: 95.8 ±13.2 cm; glycated hemoglobin (HbA1c): 5.7 ±0.3%) and 93 age and waist circumference-matched healthy male controls (age: 33 ±7.3 years; BMI: 26.1 ±3.9 kg/m2; waist circumference: 94.6 ±11.9 cm; HbA1c: 5.7 ±0.3%) participated in this cross-sectional study. Blood was sampled in the fasting state and 90 min after ingestion of a standardized liquid meal (2,268 kJ).
Results
Compared to healthy controls, patients were characterized by elevated fasting levels of glucose, proinsulin, C-peptide and glucose-dependent insulinotropic polypeptide (GIP) and higher postprandial levels of insulin, proinsulin, C-peptide and GIP. Also, patients exhibited elevated plasma levels of C-reactive protein and signs of dyslipidemia. Fasting plasma levels of insulin, glucagon, glucagon-like peptide-1 (GLP-1), ghrelin, leptin, adiponectin, tumor necrosis factor-alpha, plasminogen activator inhibitor 1, interleukin 6 and postprandial levels of glucagon, GLP-1, ghrelin, leptin and adiponectin did not differ between groups.
Discussion
Presenting with an insulin resistant-like pattern, including beta cell hypersecretion and elevated GIP levels, non-diabetic antipsychotic-treated patients display emerging signs of dysmetabolism and a compromised cardiovascular risk profile. The appetite regulating hormones, GLP-1 and ghrelin appear not to be influenced by antipsychotic treatment. Our findings provide new clinical insight into the pathophysiology behind metabolic side-effects of antipsychotics, and put emphasis on the importance of implementing metabolic screening into psychiatric practice.
Treatment with antipsychotic drugs is widely associated with metabolic side-effects such as overweight and disturbed glucose metabolism, but the pathophysiological mechanisms are unclear.
Methods
Fifty-one non-diabetic, antipsychotic-treated male patients ((mean±standard deviation) age: 33.1 ±6.7 years; body mass index (BMI) 26.0 ±4.7 kg/m2; waist circumference: 95.8 ±13.2 cm; glycated hemoglobin (HbA1c): 5.7 ±0.3%) and 93 age and waist circumference-matched healthy male controls (age: 33 ±7.3 years; BMI: 26.1 ±3.9 kg/m2; waist circumference: 94.6 ±11.9 cm; HbA1c: 5.7 ±0.3%) participated in this cross-sectional study. Blood was sampled in the fasting state and 90 min after ingestion of a standardized liquid meal (2,268 kJ).
Results
Compared to healthy controls, patients were characterized by elevated fasting levels of glucose, proinsulin, C-peptide and glucose-dependent insulinotropic polypeptide (GIP) and higher postprandial levels of insulin, proinsulin, C-peptide and GIP. Also, patients exhibited elevated plasma levels of C-reactive protein and signs of dyslipidemia. Fasting plasma levels of insulin, glucagon, glucagon-like peptide-1 (GLP-1), ghrelin, leptin, adiponectin, tumor necrosis factor-alpha, plasminogen activator inhibitor 1, interleukin 6 and postprandial levels of glucagon, GLP-1, ghrelin, leptin and adiponectin did not differ between groups.
Discussion
Presenting with an insulin resistant-like pattern, including beta cell hypersecretion and elevated GIP levels, non-diabetic antipsychotic-treated patients display emerging signs of dysmetabolism and a compromised cardiovascular risk profile. The appetite regulating hormones, GLP-1 and ghrelin appear not to be influenced by antipsychotic treatment. Our findings provide new clinical insight into the pathophysiology behind metabolic side-effects of antipsychotics, and put emphasis on the importance of implementing metabolic screening into psychiatric practice.
| Original language | English |
|---|---|
| Publication date | Apr 2014 |
| Number of pages | 1 |
| Publication status | Published - Apr 2014 |
| Event | 4th Schizophrenia International Research Society Conference - Firenze Fiera Congress Center, Firenze, Italy Duration: 5 Apr 2014 → 9 Apr 2014 |
Conference
| Conference | 4th Schizophrenia International Research Society Conference |
|---|---|
| Location | Firenze Fiera Congress Center |
| Country/Territory | Italy |
| City | Firenze |
| Period | 05/04/2014 → 09/04/2014 |